国产与进口瑞舒伐他汀治疗原发性高脂血症的药物经济学研究.

OBJECTIVE:To probe into the economical efficiency of domestic and imported rosuvastatin in treatment of essential hyperlipidemia. METHODS: 1 749 patients with essential hyperlipemia admitted into Laiwu Central Hospital of Xinwen Mining Group from Jan. 2015 to Dec. 2017 were retrospectively selected and divided into group A (857 cases) and group B (892 cases) through different medications. Patients in group A was given domestic rosuvastatin, while group B received imported rosuvastatin. Difference of serum levels [serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C), lipid-regulating efficacy, adverse drug reactions and cost-effectiveness analysis of two groups were compared. RESULTS: After treatment of 12 weeks, the TC, LDL-C level of two groups decreased significantly compared with before treatment, yet there was no statistically significant difference between two groups in TC, TG, LDL-C and HDL-C (P >0.05). The total lipid-regulating efficacy of group A and group B were respectively 94.28% (808/857) and 94.17% (840/892), without any statistically significant difference (P> 0.05). One patient in group A developed mild liver drug enzymes, and one patient in group B developed mild diarrhea, which did not affect continued medication, and no other expenses were incurred. The drug cost and cost-effectiveness ratio of patients in group A were significantly lower than those in group B, and the difference was statistically significant (P < 0.05). Patients in group A saved 344.4 yuan for 12 weeks of treatment. CONCLUSIONS: Compared with imported rosuvastatin, domestic rosuvastatin is more economical in treatment of essential hyperlipidemia. [ABSTRACT FROM AUTHOR]

目的:探讨国产与进口瑞舒伐他汀治疗原发性高脂血症的经济性.方法:回顾性选取2015年1月至2017年12月新汶矿业集团莱芜中心医院收治的原发性高脂血症患者1749例,按照所用药物的不同分为A组857例与B组892例.A组患者给予国产瑞舒伐他汀片,B组患者给予进口瑞舒伐他汀片.比较两组患者的血脂水平[血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)]、调脂疗效、不良反应及成本-效果分析的差异.结果:治疗12周后,两组患者TC、LDL-C水平较治疗前明显降低,但两组患者TC、TG、LDL-C及HDL-C水平的差异均无统计学意义(P>0.05);A、B组患者调脂总有效率分别为94.28％(808/857)、94.17％(840/892),差异无统计学意义(P>0.05);A组1例患者发生轻微肝药酶升高,B组1例患者发生轻微腹泻,未影响继续用药,未产生其他费用;A组患者药物成本、成本-效果比明显低于B组,差异均有统计学意义(P<0.05);A组患者治疗12周节省费用344.4元.结论:与进口瑞舒伐他汀相比,国产瑞舒伐他汀治疗原发性高脂血症更经济. [ABSTRACT FROM AUTHOR]